Brincidofovir is an oral antiviral drug being developed as a potential prevention or treatment for life-threatening viral diseases. It works by keeping viruses from creating additional copies of themselves.
Brincidofovir is in Phase 3 clinical testing against cytomegalovirus (CMV) and adenovirus (AdV) but has been given to patients with many other life-threatening viral infections through an Expanded Access trial that was completed in 2012. The safety database of over 1000 individuals exposed to BCV has supported progression into Phase 3 trials.
Patients in the U.S. have been treated with brincidofovir for Ebola Virus Disease at the request of treating physicians. Emergency Investigational New Drug Applications (EINDs) have been approved by the U.S. Food and Drug Administration (FDA) for the use of brincidofovir in patients with confirmed Ebola Virus Disease.
Patient Ratings for
How was your experience with ?
Brincidofovir Drug Class
Brincidofovir is part of the drug class: